KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $177.1 million.

  • Halozyme Therapeutics' Total Current Liabilities rose 2731.27% to $177.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $177.1 million, marking a year-over-year increase of 2731.27%. This contributed to the annual value of $177.1 million for FY2025, which is 2731.27% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Total Current Liabilities stood at $177.1 million for Q4 2025, which was up 2731.27% from $837.2 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Total Current Liabilities peaked at $837.2 million during Q3 2025, and registered a low of $91.9 million during Q1 2023.
  • In the last 5 years, Halozyme Therapeutics' Total Current Liabilities had a median value of $116.8 million in 2021 and averaged $162.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 7219.95% in 2021, then skyrocketed by 66940.5% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' Total Current Liabilities (Quarter) stood at $117.1 million in 2021, then grew by 11.65% to $130.8 million in 2022, then decreased by 13.99% to $112.5 million in 2023, then rose by 23.65% to $139.1 million in 2024, then rose by 27.31% to $177.1 million in 2025.
  • Its Total Current Liabilities was $177.1 million in Q4 2025, compared to $837.2 million in Q3 2025 and $134.3 million in Q2 2025.